Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.
Pharmacoeconomics. 2001; 19(4):411-20.P

Abstract

OBJECTIVE

To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI).

DESIGN AND SETTING

The cost-effectiveness analysis of n-3 PUFA treatment after MI was based on morbidity and mortality data and the use of resources obtained prospectively during the 3.5 year follow-up period of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione study. The cost-effectiveness analysis took into account the incremental number of life-years gained and the incremental costs for hospital admissions, diagnostic tests and drugs, applying a 5% discount rate. The value for money of n-3 PUFA treatment was assessed using the cost-effectiveness ratio and the number needed to treat (NNT) approach.

PERSPECTIVE

Third-party payer.

MAIN OUTCOME MEASURES AND RESULTS

The incremental cost-effectiveness ratio for n-3 PUFA in the basecase scenario was 24,603 euro (EUR, 1999 values) per life-year gained (95% confidence interval: 22,646 to 26,930). Sensitivity analysis included the analysis of extremes, producing estimates varying from EUR15,721 to EUR52,524 per life-year gained. 172 patients would need to be treated per year with n-3 PUFA, at an annual cost of EUR68,000, in order to save 1 patient. This is comparable with the NNT value, and associated annual cost for simvastatin, but less costly than that for pravastatin.

CONCLUSIONS

The cost effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after MI. Since the clinical benefit provided by n-3 PUFA is additive, this therapy should be added to the established routine practice, with additive costs.

Authors+Show Affiliations

Department of Cardiovascular Research, Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy. franzosi@marionegri.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11383757

Citation

Franzosi, M G., et al. "Cost-effectiveness Analysis of N-3 Polyunsaturated Fatty Acids (PUFA) After Myocardial Infarction: Results From Gruppo Italiano Per Lo Studio Della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial." PharmacoEconomics, vol. 19, no. 4, 2001, pp. 411-20.
Franzosi MG, Brunetti M, Marchioli R, et al. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics. 2001;19(4):411-20.
Franzosi, M. G., Brunetti, M., Marchioli, R., Marfisi, R. M., Tognoni, G., & Valagussa, F. (2001). Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. PharmacoEconomics, 19(4), 411-20.
Franzosi MG, et al. Cost-effectiveness Analysis of N-3 Polyunsaturated Fatty Acids (PUFA) After Myocardial Infarction: Results From Gruppo Italiano Per Lo Studio Della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics. 2001;19(4):411-20. PubMed PMID: 11383757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. AU - Franzosi,M G, AU - Brunetti,M, AU - Marchioli,R, AU - Marfisi,R M, AU - Tognoni,G, AU - Valagussa,F, AU - ,, PY - 2001/6/1/pubmed PY - 2001/6/15/medline PY - 2001/6/1/entrez SP - 411 EP - 20 JF - PharmacoEconomics JO - Pharmacoeconomics VL - 19 IS - 4 N2 - OBJECTIVE: To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI). DESIGN AND SETTING: The cost-effectiveness analysis of n-3 PUFA treatment after MI was based on morbidity and mortality data and the use of resources obtained prospectively during the 3.5 year follow-up period of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione study. The cost-effectiveness analysis took into account the incremental number of life-years gained and the incremental costs for hospital admissions, diagnostic tests and drugs, applying a 5% discount rate. The value for money of n-3 PUFA treatment was assessed using the cost-effectiveness ratio and the number needed to treat (NNT) approach. PERSPECTIVE: Third-party payer. MAIN OUTCOME MEASURES AND RESULTS: The incremental cost-effectiveness ratio for n-3 PUFA in the basecase scenario was 24,603 euro (EUR, 1999 values) per life-year gained (95% confidence interval: 22,646 to 26,930). Sensitivity analysis included the analysis of extremes, producing estimates varying from EUR15,721 to EUR52,524 per life-year gained. 172 patients would need to be treated per year with n-3 PUFA, at an annual cost of EUR68,000, in order to save 1 patient. This is comparable with the NNT value, and associated annual cost for simvastatin, but less costly than that for pravastatin. CONCLUSIONS: The cost effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after MI. Since the clinical benefit provided by n-3 PUFA is additive, this therapy should be added to the established routine practice, with additive costs. SN - 1170-7690 UR - https://www.unboundmedicine.com/medline/citation/11383757/Cost_effectiveness_analysis_of_n_3_polyunsaturated_fatty_acids__PUFA__after_myocardial_infarction:_results_from_Gruppo_Italiano_per_lo_Studio_della_Sopravvivenza_nell'Infarto__GISSI__Prevenzione_Trial_ L2 - https://dx.doi.org/10.2165/00019053-200119040-00008 DB - PRIME DP - Unbound Medicine ER -